Aurinia Pharmaceuticals (AUPH) Reports In-Line Q2 EPS, narrows guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $57.2 million versus the consensus estimate of $54.25 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2024 revenue of $210-220 million, versus the consensus of $227.1 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
• BMO Capital on Constellation Brands (STZ): 'Improving, but Still Choppy'
• Tesla (TSLA) PT Raised to $430 at Truist Securities